These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 29782778)
41. Electrophysiological effects of ivabradine in dog and human cardiac preparations: potential antiarrhythmic actions. Koncz I; Szél T; Bitay M; Cerbai E; Jaeger K; Fülöp F; Jost N; Virág L; Orvos P; Tálosi L; Kristóf A; Baczkó I; Papp JG; Varró A Eur J Pharmacol; 2011 Oct; 668(3):419-26. PubMed ID: 21821019 [TBL] [Abstract][Full Text] [Related]
42. The 'Sicilian Gambit'. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. The Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J; 1991 Oct; 12(10):1112-31. PubMed ID: 1723682 [TBL] [Abstract][Full Text] [Related]
44. Classification of antiarrhythmic drugs. Kutalek SP; McCormick DJ Am Fam Physician; 1988 Oct; 38(4):261-6. PubMed ID: 2902778 [No Abstract] [Full Text] [Related]
45. The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation; 1991 Oct; 84(4):1831-51. PubMed ID: 1717173 [TBL] [Abstract][Full Text] [Related]
47. Clinical pharmacology of antiarrhythmic drugs: variability of metabolism and dose requirements. Follath F J Cardiovasc Pharmacol; 1991; 17 Suppl 6():S74-6. PubMed ID: 1723123 [TBL] [Abstract][Full Text] [Related]
48. [Electrophysiologic effects of intravenous cibenzoline succinate, a new class I antiarrhythmic agent]. Atarashi H; Iida K; Kou M; Hirayama Y; Gotoh M; Ino T; Katoh T; Hayakawa H Kokyu To Junkan; 1988 Oct; 36(10):1119-24. PubMed ID: 3247527 [No Abstract] [Full Text] [Related]
50. Class IB antiarrhythmic drugs: tocainide, mexiletine, and moricizine. Snyder DW J La State Med Soc; 1989 May; 141(5):21-5. PubMed ID: 2499645 [TBL] [Abstract][Full Text] [Related]
51. [Current classification of anti-arrhythmia agents]. Weirich J; Wenzel W Z Kardiol; 2000; 89 Suppl 3():62-7. PubMed ID: 10810787 [TBL] [Abstract][Full Text] [Related]
52. [Experimental arrhythmia models. Critical study of correlations with arrhythmias observed in clinical practice]. Dupuis BA; Vincent AC Arch Mal Coeur Vaiss; 1981 Dec; 74 Spec No():17-27. PubMed ID: 6803699 [TBL] [Abstract][Full Text] [Related]
53. Safety of use of antiarrhythmic drugs. Mehta D; Saxena A Indian Heart J; 1990; 42(6):445-50. PubMed ID: 2098318 [No Abstract] [Full Text] [Related]
54. Clinical applications of antiarrhythmic drugs. Lavenne F; de Jonghe D Acta Cardiol Suppl; 1980; (25):27-42. PubMed ID: 6155012 [No Abstract] [Full Text] [Related]
55. Rational basis of antiarrhythmic therapy: clinical pharmacology of commonly used antiarrhythmic drugs. Singh BN Angiology; 1978 Mar; 29(3):206-42. PubMed ID: 347988 [No Abstract] [Full Text] [Related]
56. Antiarrhythmic drug trials: what lessons have we learned? Gambhir DS; Batra R Indian Heart J; 1997; 49(4):435-8. PubMed ID: 9358675 [No Abstract] [Full Text] [Related]